Kura Oncology COO Kathleen Ford Sells 10,574 Shares

What Happened

• Kathleen Ford, Chief Operating Officer of Kura Oncology (KURA), sold a total of 10,574 shares in two open-market transactions. She disposed of 6,906 shares on 2026-09-28 for $10.50 each ($72,494) and 3,668 shares on 2026-09-29 at a weighted average price of $10.75 ($39,437), for total proceeds of about $111,931. These were sales (not purchases), commonly interpreted as routine liquidity rather than a bullish insider buy.

Key Details

• Transaction dates and prices:
  • 2026-09-28: 6,906 shares sold at $10.50 — $72,494.
  • 2026-09-29: 3,668 shares sold at a weighted average $10.75 (trades ranged $10.57–$10.87) — $39,437.
• Total shares sold: 10,574; total proceeds: ~$111,931.
• Shares owned after the transactions: Not specified in the filing provided.
• Footnotes / notable items:
  • The sales relate to the vesting of performance-based restricted stock units (PSUs) granted May 31, 2023; 1/6th of the underlying shares vested following the one-year anniversary of a specified development milestone (vest date determined 2026-09-27).
  • The shares sold were acquired upon PSU vesting and the sales were effected under a Rule 10b5-1 trading plan adopted May 29, 2026.
  • Part of the sale was a sell-to-cover transaction to satisfy tax withholding obligations tied to the PSU vesting.
• Filing timeliness: Form 4 filed 2026-09-29 reporting transactions on 2026-09-28 and 2026-09-29; this appears to be a timely filing.

Context

• PSUs are contingent awards that convert to shares only if specified development milestones and service conditions are met; here, a milestone anniversary triggered the vesting of 1/6th of the award.
• The combination of PSU vesting, sell-to-cover for taxes, and execution under a pre-established 10b5-1 plan indicates these sales were administrative/liquidity-driven rather than a discretionary signal about company prospects.